Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Evotec SE    EVT   DE0005664809

EVOTEC SE

(EVT)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Evotec : to acquire Just Biotherapeutics, Inc.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/20/2019 | 04:30pm EDT

DGAP-Ad-hoc: Evotec SE / Key word(s): Takeover
Evotec SE to acquire Just Biotherapeutics, Inc.

20-May-2019 / 22:24 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Hamburg, Germany - Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809, WKN 566480) announced today the signing of a definitive agreement under which Evotec will acquire Just Biotherapeutics, Inc. ("Just.Bio") based in Seattle, WA, USA for up to US$ 90 m (approx. EUR 81 m; EUR/$ fx rate of 1.117) including potential performance-based earn-out components expected within the next three years. The acquisition of 100% of the issued and outstanding equity interests of the company will be paid in cash.

Just.Bio is a unique technology company that integrates highly synergistic scientific expertise and technologies for design, development, and manufacturing of biologics. The acquisition grows Evotec's business into a comprehensive offering including biologics in therapeutic areas such as oncology, CNS, pain, inflammation, metabolics, and infectious diseases. Just.Bio has approx. 90 employees, mainly scientists, all working at a state-of-the-art discovery, development and manufacturing facility in Seattle, WA, USA.

The completion of the transaction is subject to customary closing conditions. The acquisition is expected to close in the second quarter of 2019.

- End of ad hoc notification -

Contact: Dr Werner Lanthaler, Chief Executive Officer, Evotec SE, Manfred Eigen Campus, Essener Bogen 7, 22419 Hamburg, Germany, Phone: +49(0)40560 81-242, werner.lanthaler@evotec.com


20-May-2019 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Evotec SE
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Phone: +49 (0)40 560 81-0
Fax: +49 (0)40 560 81-222
E-mail: info@evotec.com
Internet: www.evotec.com
ISIN: DE0005664809
WKN: 566480
Indices: MDAX, TecDAX
Listed: Regulated Market in Berlin, Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 813731

 
End of Announcement DGAP News Service

813731  20-May-2019 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=813731&application_name=news&site_id=zonebourse

© EQS 2019
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on EVOTEC SE
09/11EVOTEC SE : Release according to Article 40, Section 1 of the WpHG [the German S..
EQ
09/09EVOTEC : to attend upcoming investor conferences
AQ
09/06EVOTEC : To attend upcoming investor conferences
EQ
09/03EVOTEC SE : Notification and public disclosure of transactions by persons
EQ
08/30EVOTEC SE : Release according to Article 40, Section 1 of the WpHG [the German S..
EQ
08/30EVOTEC SE : Release according to Article 41 of the WpHG [the German Securities T..
EQ
08/23EVOTEC SE : Release according to Article 40, Section 1 of the WpHG [the German S..
EQ
08/19EVOTEC SE : Notification and public disclosure of transactions by persons
EQ
08/15EVOTEC : reports first half-year 2019 results and corporate updates
AQ
08/14EVOTEC : Reports first half-year 2019 results and corporate updates
EQ
More news
Financials (EUR)
Sales 2019 428 M
EBIT 2019 62,5 M
Net income 2019 41,9 M
Finance 2019 62,0 M
Yield 2019 -
P/E ratio 2019 71,6x
P/E ratio 2020 53,5x
EV / Sales2019 7,12x
EV / Sales2020 6,35x
Capitalization 3 105 M
Chart EVOTEC SE
Duration : Period :
Evotec SE Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EVOTEC SE
Short TermMid-TermLong Term
TrendsBullishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Average target price 28,80  €
Last Close Price 20,77  €
Spread / Highest target 58,9%
Spread / Average Target 38,7%
Spread / Lowest Target 20,4%
EPS Revisions
Managers
NameTitle
Werner Lanthaler Chief Executive Officer
Wolfgang Plischke Chairman-Supervisory Board
Craig L. Johnstone Chief Operating Officer & Member-Management Board
Enno Spillner Chief Financial Officer
Cord E. Dohrmann Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
EVOTEC SE19.32%3 417
IQVIA HOLDINGS INC33.94%30 481
LONZA GROUP35.89%25 846
CELLTRION, INC.--.--%18 845
INCYTE CORPORATION22.85%17 466
EXACT SCIENCES CORPORATION64.77%13 463